Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Notable Analyst Calls This Week: Microsoft, Starbucks and GM Among Top Picks
J&J, Legend Report Carvykti Cut Death Risk by 45% in Multiple Myeloma Study
J&J Releases Encouraging Data on Talvey Combination Therapies
Johnson & Johnson's CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After...
Achieve, INmune, Lenz Gain on Bullish Initiations From Raymond James
steven smith38 : st d. no need to apologize. u are a blessing to the poor.